Navigation Links
RBC Life Sciences Announces 2009 Year End Results
Date:3/11/2010

IRVING, Texas, March 11 /PRNewswire-FirstCall/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) — RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, reported today company-wide net sales of $24.9 million for the year ended December 31, 2009, compared to net sales of $30.4 million for the same period during 2008.

The company also reported a net loss of $335,000, or $0.02 per diluted share, during 2009, compared to net earnings of $1.6 million, or $0.07 per diluted share, during 2008.

"In 2009, our international licensees were hobbled by the global economy overseas, which contributed disproportionately to our decline in sales," said RBC Life Sciences President and CEO John W. Price. "We did, however, see sales in this channel begin to increase late in the year as global economic conditions also began to show signs of improvement.  A bright spot in 2009 was the growth of our North American network marketing base. Sales domestically grew more than 4% percent in 2009 compared to the previous year."

Mr. Price also said that RBC Life Sciences is now compliant with industry-wide, FDA-required Good Manufacturing Practices (GMP). "The company invested substantial resources to achieve GMP compliance during 2009 and will continue to do so annually to maintain our GMP status," said Mr. Price. GMPs ensure that companies adhere to practices that promote product safety, quality and efficacy.

About RBC Life Sciences
Through U.S. and Canadian subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. MPM Medical, the company's medical products subsidiary, develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

    
    
    
                              RBC Life Sciences, Inc.
                           Summary Results of Operations
                       (in thousands, except per share data)
                                    (unaudited)
    
                                                  Years Ended December 31,
                                                  ------------------------
                                                 2009                  2008
                                                 ----                  ----
    
    Net sales                                 $24,925               $30,409
    Gross profit                               12,802                15,494
    Operating profit (loss)                      (160)                2,852
    Earnings (loss) before income taxes          (324)                2,677
    Provision for income taxes                     11                 1,061
    Net earnings (loss)                          (335)                1,616
    
    Earnings (loss) per share – basic          $(0.02)                $0.08
    Earnings (loss) per share – diluted         (0.02)                 0.07
    
    
    Weighted average shares
     outstanding – basic                       21,921                21,465
    Weighted average shares
     outstanding – diluted                     21,921                22,839
    
    
    
    
    
    
                             RBC Life Sciences, Inc.
                            Condensed Balance Sheets
                                 (in thousands)
                                   (unaudited)
    
                                         December 31,          December 31,
                                         ------------          ------------
                                                 2009                  2008
                                                 ----                  ----
    Assets
    Cash and cash equivalents                  $3,972                $4,973
    Inventories                                 5,344                 5,707
    Other current assets                        1,914                 2,245
                                                -----                 -----
      Total current assets                     11,230                12,925
    Other assets                                7,383                 6,841
                                                -----                 -----
      Total assets                            $18,613               $19,766
                                              =======               =======
    
    Liabilities and shareholders' equity
    Accounts payable and accrued
     liabilities                               $2,729                $3,228
    Deferred revenue                            3,669                 4,279
    Other current liabilities                     156                   144
                                                  ---                   ---
      Total current liabilities                 6,554                 7,651
    Other liabilities                           2,840                 2,728
    Shareholders' equity                        9,219                 9,387
                                                -----                 -----
      Total liabilities and
       shareholders' equity                   $18,613               $19,766
                                              =======               =======
    
    
    

SOURCE RBC Life Sciences, Inc.

Back to top

RELATED LINKS
http://www.rbclifesciences.com

'/>"/>

SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. FriendsofWater.com Responds to the National Acadamy of Sciences Report that Millions of Americans Get Sick Yearly from Contaminated Water
2. Moravia Worldwide to Present Webinar on Life Sciences Translation 101
3. SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program
4. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
5. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
6. Vista LifeSciences Partners with Vangard Voice Systems to Voice-Enable Medical Data Collection
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
8. Gems Medical Sciences Created to Focus on Medical & Life Science Fluid Handling
9. AMD Global Telemedicine Inc. and Texas Tech University Health Sciences Center Bring High-Tech Health Care to Children of Texas
10. Bariatric Advantage, a Division of Catalina Lifesciences, Inc. Announces Appointment of Bret Petkus to Vice-President of North American Sales.
11. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... healthcare industry, ranked among the top five firms in the “2015/2016 Best in ... Implementation Support and Staffing. KLAS is a research and insights firm on a ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... and Reconstructive Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and ... surgery . Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... clinical decision support technology, with highly adaptable algorithms, has been updated to help ... has signs and symptoms consistent with Zikas and a travel history to affected ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you ... Ray Clarke poses a question as a challenge for his readers to examine ... in the Being" (published by Partridge Singapore), Clarke explores the subject with more ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016   Health 2.0 , the ... health technologies, announced today " 10 Year Global Retrospective ... tech over the past ten years.   ... decade, Health 2.0 has served as the preeminent thought-leader ... with thousands of technologies, companies, innovators, and patient-activists through ...
(Date:2/11/2016)...  AfterPill.com is reporting that this week,s Centers for ... women who are at risk of unintended pregnancy impacts ... raises the risks of unprotected sex in particular.  ... to the Guttmacher Institute, there are 43 million women ... who have sex without the intention of becoming pregnant.  ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and ... --> Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and ... future growth with most robust pipeline in Shire , ... growth with most robust pipeline in Shire , ...
Breaking Medicine Technology: